Annalisa Deodati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annalisa Deodati has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
- Stefano Cianfarani
Diabetology and Growth Disorders Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
23 shared publications - Amalia Gastaldelli
Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche (CNR), Pisa, Italy
6 shared publications - Cinzia La Rocca
Center for Gender-Specific Medicine, Italian National Institute of Health, 00161 Rome, Italy
6 shared publications - Francesca Maranghi
Center for Gender-Specific Medicine, Italian National Institute of Health, 00161 Rome, Italy
6 shared publications - Luca Busani
Istituto Superiore di Sanità, Rome, Italy
6 shared publications - Roberta Tassinari
Center for Gender-Specific Medicine, Italian National Institute of Health, 00161 Rome, Italy
6 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1874027
Precocious puberty in boys: current insights into etiology, genetic advances, and environmental factors
Background: Central precocious puberty (CPP) in males results from the premature activation of the hypothalamic–pituitary–gonadal (HPG) axis, clinically diagnosed by a testicular volume >4 mL before the age of 9 years. Over the past two decades, a clear secular trend toward earlier pubertal onset has been reported. Historically, CPP in boys was strongly associated with intracranial lesions, observed in 40–50% of cases. Recent findings: Over the last decade, converging evidence has indicated a markedly lower prevalence of brain lesions in males with CPP, approximately 6–8%. Identified risk factors for intracranial lesions include neurological symptoms, pubertal onset before 8 years, and maternal age at menarche above 11 years. These data support a more selective, risk-based approach to neuroimaging and highlight the need to re-define a new consensus, recently published. Idiopathic CPP represents the majority of cases also in males, with increasing evidence supporting a strong genetic basis. Key mutations include gain-of-function variants in KISS1 and KISS1R, as well as loss-of-function mutations in MKRN3 and DLK1. Additional candidate genes—LIN28B, GABRA1, NPYR, TAC3, and TACR3—have been recently linked to pubertal regulation, although their precise mechanistic roles remain unclear. Beyond genetics, environmental exposures, particularly to endocrine-disrupting chemicals (EDCs), have been implicated in modulating pubertal timing. Conclusion: CPP in boys results from a multifactorial interplay between genetic predisposition and environmental influences. This review summarizes recent evidence regarding the prevalence of brain lesions, emerging genetic discoveries, and the role of endocrine disruptors, to promote a more personalized and precise diagnostic algorithm.
- 16 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1874027
Open AccessPrecocious puberty in boys: current insights into etiology, genetic advances, and environmental factors
Background: Central precocious puberty (CPP) in males results from the premature activation of the hypothalamic–pituitary–gonadal (HPG) axis, clinically diagnosed by a testicular volume >4 mL before the age of 9 years. Over the past two decades, a clear secular trend toward earlier pubertal onset has been reported. Historically, CPP in boys was strongly associated with intracranial lesions, observed in 40–50% of cases. Recent findings: Over the last decade, converging evidence has indicated a markedly lower prevalence of brain lesions in males with CPP, approximately 6–8%. Identified risk factors for intracranial lesions include neurological symptoms, pubertal onset before 8 years, and maternal age at menarche above 11 years. These data support a more selective, risk-based approach to neuroimaging and highlight the need to re-define a new consensus, recently published. Idiopathic CPP represents the majority of cases also in males, with increasing evidence supporting a strong genetic basis. Key mutations include gain-of-function variants in KISS1 and KISS1R, as well as loss-of-function mutations in MKRN3 and DLK1. Additional candidate genes—LIN28B, GABRA1, NPYR, TAC3, and TACR3—have been recently linked to pubertal regulation, although their precise mechanistic roles remain unclear. Beyond genetics, environmental exposures, particularly to endocrine-disrupting chemicals (EDCs), have been implicated in modulating pubertal timing. Conclusion: CPP in boys results from a multifactorial interplay between genetic predisposition and environmental influences. This review summarizes recent evidence regarding the prevalence of brain lesions, emerging genetic discoveries, and the role of endocrine disruptors, to promote a more personalized and precise diagnostic algorithm.
- Open Access
Transitioning Adolescents and Young Adults with Type 1 Diabetes Mellitus in Italy: A Scoping Review
Background/Objectives: Worldwide, Type 1 diabetes mellitus (T1DM) in youth represents a growing public health concern, and Italy is among the countries with the highest incidence in the pediatric population. The transition from pediatric to adult care is a vulnerable period associated with increased risks of acute complications and long-term morbidity. This scoping review aimed to map the available Italian evidence on healthcare transition in adolescents and young adults (AYAs) with T1DM, addressing five key areas: characteristics of the transition process and involved populations, emotional and psychological experiences, the role of technology, existing transitional care models and related outcomes, and assessment criteria and tools for transition readiness. Methods: This review followed the JBI methodology and included studies focused on Italian AYAs (aged 10–24 years) with T1DM. Study selection was documented using the PRISMA flow chart. Results: Twenty studies were included. The evidence revealed a heterogeneous and inconsistently implemented transition landscape. Several structured transition projects were identified, differing in multidisciplinary team composition, organization, and outcome evaluation. Emotional distress, fear of separation from pediatric providers, and variable satisfaction with transition experiences were commonly reported. Adoption of technologies increased over time and was associated with improved clinical outcomes, although overall uptake remained suboptimal. Importantly, no Italian-validated tools for assessing transition readiness were identified. Conclusions: Transitional care for Italian AYAs with T1DM is increasingly recognized but remains insufficiently standardized and evaluated. Future research should prioritize multicenter studies, stratified analyses, and the development of culturally validated readiness assessment tools to support effective and individualized transitions.
Open AccessTransitioning Adolescents and Young Adults with Type 1 Diabetes Mellitus in Italy: A Scoping Review
Background/Objectives: Worldwide, Type 1 diabetes mellitus (T1DM) in youth represents a growing public health concern, and Italy is among the countries with the highest incidence in the pediatric population. The transition from pediatric to adult care is a vulnerable period associated with increased risks of acute complications and long-term morbidity. This scoping review aimed to map the available Italian evidence on healthcare transition in adolescents and young adults (AYAs) with T1DM, addressing five key areas: characteristics of the transition process and involved populations, emotional and psychological experiences, the role of technology, existing transitional care models and related outcomes, and assessment criteria and tools for transition readiness. Methods: This review followed the JBI methodology and included studies focused on Italian AYAs (aged 10–24 years) with T1DM. Study selection was documented using the PRISMA flow chart. Results: Twenty studies were included. The evidence revealed a heterogeneous and inconsistently implemented transition landscape. Several structured transition projects were identified, differing in multidisciplinary team composition, organization, and outcome evaluation. Emotional distress, fear of separation from pediatric providers, and variable satisfaction with transition experiences were commonly reported. Adoption of technologies increased over time and was associated with improved clinical outcomes, although overall uptake remained suboptimal. Importantly, no Italian-validated tools for assessing transition readiness were identified. Conclusions: Transitional care for Italian AYAs with T1DM is increasingly recognized but remains insufficiently standardized and evaluated. Future research should prioritize multicenter studies, stratified analyses, and the development of culturally validated readiness assessment tools to support effective and individualized transitions.
- Open Access
- 17 April 2025
- Published by Springer Nature in Acta Diabetologica
- Vol. 62 (9) , 1-3
DKA in a toddler negative to type 1 diabetes autoantibodies: unusual presentation of Kearn–Sayre syndrome
- 17 April 2025
- Published by Springer Nature in Acta Diabetologica
- Vol. 62 (9) , 1-3
Open AccessDKA in a toddler negative to type 1 diabetes autoantibodies: unusual presentation of Kearn–Sayre syndrome
- Open Access
- 4 November 2024
- Published by MDPI AG in Diabetology
- Vol. 5 (6) , 584-599
Exploration of Foundational Models for Blood Glucose Forecasting in Type-1 Diabetes Pediatric Patients
Aims: The accurate prediction of blood glucose (BG) levels is critical for managing Type-1 Diabetes (T1D) in pediatric patients, where variability due to factors like physical activity and developmental changes presents significant challenges. Methods: This work explores the application of foundational models, particularly the encoder–decoder model TimeGPT, for BG forecasting in T1D pediatric patients. Methods: The performance of TimeGPT is compared against state-of-the-art models, including ARIMAX and LSTM, and multilayer perceptron (MLP) architectures such as TiDE and TSMixer. The models were evaluated using continuous glucose monitoring (CGM) data and exogenous variables, such as insulin intake. Results: TimeGPT outperforms or achieves comparable accuracy to the state of the art and MLP models in short-term predictions (15 and 30 min), with most predictions falling within the clinically safe zones of the Clarke Error Grid. Conclusions: The findings suggest that foundational models like TimeGPT offer promising generalization capabilities for medical applications and can serve as valuable tools to enhance diabetes management in pediatric T1D patients.
- 4 November 2024
- Published by MDPI AG in Diabetology
- Vol. 5 (6) , 584-599
Open AccessExploration of Foundational Models for Blood Glucose Forecasting in Type-1 Diabetes Pediatric Patients
Aims: The accurate prediction of blood glucose (BG) levels is critical for managing Type-1 Diabetes (T1D) in pediatric patients, where variability due to factors like physical activity and developmental changes presents significant challenges. Methods: This work explores the application of foundational models, particularly the encoder–decoder model TimeGPT, for BG forecasting in T1D pediatric patients. Methods: The performance of TimeGPT is compared against state-of-the-art models, including ARIMAX and LSTM, and multilayer perceptron (MLP) architectures such as TiDE and TSMixer. The models were evaluated using continuous glucose monitoring (CGM) data and exogenous variables, such as insulin intake. Results: TimeGPT outperforms or achieves comparable accuracy to the state of the art and MLP models in short-term predictions (15 and 30 min), with most predictions falling within the clinically safe zones of the Clarke Error Grid. Conclusions: The findings suggest that foundational models like TimeGPT offer promising generalization capabilities for medical applications and can serve as valuable tools to enhance diabetes management in pediatric T1D patients.
- Open Access
- 16 November 2023
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 97 (4) , 388-396
Urinary Bisphenol A and Bis(2-Ethylhexyl) Phthalate Metabolite Concentrations in Children with Obesity: A Case-Control Study
Introduction: Obesity is a worldwide public health problem. Experimental animal and in vitro studies suggest that the exposure to BPA and phthalates are associated to a higher risk of obesity. Objective: The objective of the study was to determine urinary excretion of bisphenol A and phthalates in obese and normal weight children. Methods: A case-control study was conducted in 122 children. Sixty-six obese children, 36 girls (mean age 8.41 ± 1.27 years), and 30 boys (mean age 8.51 ± 1.33 years) and 56 normal weight children, 27 girls (mean age 7.64 ± 1.49 years), and 29 boys (mean age 7.77 ± 1.56 years) were studied. Urinary BPA and bis(2-ethylhexyl) phthalate (DEHP) metabolites (MEHP, MEHHP, and MEOHP) were measured, respectively, by gas chromatography and high-performance liquid chromatography. Individual determinants of exposure were evaluated through “ad hoc” questionnaires. Results: BPA and DEHP metabolites were detectable in obese and normal weight children. Obese girls showed significantly higher BPA concentrations in comparison with normal weight girls (means 10.77, 95% CI = 7.02–16.53 vs. 5.50, 95% CI = 3.93–7.71 μg/g creatinine, respectively, p < 0.02). The first step of DEHP metabolic rate was significantly higher in obese girls compared with controls (p < 0.05). DEHP metabolites correlated significantly with leptin concentrations in obese girls (p < 0.03). A higher risk of obesity was found in children with BPA levels above the median values with the habit to eat food packaged (OR = 11.09, 95% CI = 1.28–95.78). Conclusions: These findings show that a higher exposure to BPA is associated with the risk of obesity in girls. Further studies are needed to unveil the cause-effect relationship.
- 16 November 2023
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 97 (4) , 388-396
Open AccessUrinary Bisphenol A and Bis(2-Ethylhexyl) Phthalate Metabolite Concentrations in Children with Obesity: A Case-Control Study
Introduction: Obesity is a worldwide public health problem. Experimental animal and in vitro studies suggest that the exposure to BPA and phthalates are associated to a higher risk of obesity. Objective: The objective of the study was to determine urinary excretion of bisphenol A and phthalates in obese and normal weight children. Methods: A case-control study was conducted in 122 children. Sixty-six obese children, 36 girls (mean age 8.41 ± 1.27 years), and 30 boys (mean age 8.51 ± 1.33 years) and 56 normal weight children, 27 girls (mean age 7.64 ± 1.49 years), and 29 boys (mean age 7.77 ± 1.56 years) were studied. Urinary BPA and bis(2-ethylhexyl) phthalate (DEHP) metabolites (MEHP, MEHHP, and MEOHP) were measured, respectively, by gas chromatography and high-performance liquid chromatography. Individual determinants of exposure were evaluated through “ad hoc” questionnaires. Results: BPA and DEHP metabolites were detectable in obese and normal weight children. Obese girls showed significantly higher BPA concentrations in comparison with normal weight girls (means 10.77, 95% CI = 7.02–16.53 vs. 5.50, 95% CI = 3.93–7.71 μg/g creatinine, respectively, p < 0.02). The first step of DEHP metabolic rate was significantly higher in obese girls compared with controls (p < 0.05). DEHP metabolites correlated significantly with leptin concentrations in obese girls (p < 0.03). A higher risk of obesity was found in children with BPA levels above the median values with the habit to eat food packaged (OR = 11.09, 95% CI = 1.28–95.78). Conclusions: These findings show that a higher exposure to BPA is associated with the risk of obesity in girls. Further studies are needed to unveil the cause-effect relationship.
- Open Access
- 6 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14963
Insulin Clearance at the Pubertal Transition in Youth with Obesity and Steatosis Liver Disease
No data are available on insulin clearance (ClI) trends during the pubertal transition. The aim of this study was to investigate in 973 youths with obesity whether ClI in fasting and post-oral glucose challenge (OGTT) conditions varies at the pubertal transition in relation to the severity of obesity and the presence of steatosis liver disease (SLD). The severity of obesity was graded according to the Centers for Disease Control. SLD was graded as absent, mild and severe based on alanine amino transferase levels. ClI was defined as the molar ratio of fasting C-peptide to insulin and of the areas under the insulin to glucose curves during an OGTT. In total, 35% of participants were prepubertal, 72.6% had obesity class II, and 52.6% had mild SLD. Fasting ClI (nmol/pmol × 10−2) was significantly lower in pubertal [0.11 (0.08–0.14)] than in prepubertal individuals [0.12 (0.09–0.16)] and higher in class III [0.15 (0.11–0.16)] than in class I obesity [0.11 (0.09–0.14)]. OGTT ClI was higher in boys [0.08 (0.06–0.10)] than in girls [0.07 (0.06–0.09)]; in prepubertal [0.08 (0.06–0.11)] than in pubertal individuals [0.07 (0.05–0.09)]; in class III [0.14 (0.08–0.17)] than in class I obesity [0.07 (0.05–0.10)]; and in severe SLD [0.09 (0.04–0.14)] than in no steatosis [0.06 (0.04–0.17)]. It was lower in participants with prediabetes [0.06 (0.04–0.07)]. OGTT ClI was lower in youths with obesity at puberty along with insulin sensitivity and greater secretion. The findings suggest that the initial increase in ClI in youth with severe obesity and SLD is likely to compensate for hyperinsulinemia and its subsequent decrease at the onset of prediabetes and other metabolic abnormalities.
- 6 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14963
Open AccessInsulin Clearance at the Pubertal Transition in Youth with Obesity and Steatosis Liver Disease
No data are available on insulin clearance (ClI) trends during the pubertal transition. The aim of this study was to investigate in 973 youths with obesity whether ClI in fasting and post-oral glucose challenge (OGTT) conditions varies at the pubertal transition in relation to the severity of obesity and the presence of steatosis liver disease (SLD). The severity of obesity was graded according to the Centers for Disease Control. SLD was graded as absent, mild and severe based on alanine amino transferase levels. ClI was defined as the molar ratio of fasting C-peptide to insulin and of the areas under the insulin to glucose curves during an OGTT. In total, 35% of participants were prepubertal, 72.6% had obesity class II, and 52.6% had mild SLD. Fasting ClI (nmol/pmol × 10−2) was significantly lower in pubertal [0.11 (0.08–0.14)] than in prepubertal individuals [0.12 (0.09–0.16)] and higher in class III [0.15 (0.11–0.16)] than in class I obesity [0.11 (0.09–0.14)]. OGTT ClI was higher in boys [0.08 (0.06–0.10)] than in girls [0.07 (0.06–0.09)]; in prepubertal [0.08 (0.06–0.11)] than in pubertal individuals [0.07 (0.05–0.09)]; in class III [0.14 (0.08–0.17)] than in class I obesity [0.07 (0.05–0.10)]; and in severe SLD [0.09 (0.04–0.14)] than in no steatosis [0.06 (0.04–0.17)]. It was lower in participants with prediabetes [0.06 (0.04–0.07)]. OGTT ClI was lower in youths with obesity at puberty along with insulin sensitivity and greater secretion. The findings suggest that the initial increase in ClI in youth with severe obesity and SLD is likely to compensate for hyperinsulinemia and its subsequent decrease at the onset of prediabetes and other metabolic abnormalities.
- Open Access
- 16 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 16012
Exposure to Endocrine Disruptors (Di(2-Ethylhexyl)phthalate (DEHP) and Bisphenol A (BPA)) in Women from Different Residing Areas in Italy: Data from the LIFE PERSUADED Project
Phthalates and bisphenol A (BPA) are plasticizers used in many industrial products that can act as endocrine disruptors and lead to metabolic diseases. During the LIFE PERSUADED project, we measured the urinary concentrations of BPA and Di(2-ethylhexyl)phthalate (DEHP) metabolites in 900 Italian women representative of the Italian female adult population (living in the north, centre, and south of Italy in both rural and urban areas). The whole cohort was exposed to DEHP and BPA with measurable levels above limit of detection in more than 99% and 95% of the samples, respectively. The exposure patterns differed for the two chemicals in the three macro-areas with the highest urinary levels for DEHP in south compared to central and northern Italy and for BPA in northern compared to central and southern Italy. BPA levels were higher in women living in urban areas, whereas no difference between areas was observed for DEHP. The estimated daily intake of BPA was 0.11 μg/kg per day, about 36-fold below the current temporary tolerable daily intake of 4 μg/kg per day established by the EFSA in 2015. The analysis of cumulative exposure showed a positive correlation between DEHP and BPA. Further, the reduction of exposure to DEHP and BPA, through specific legislative measures, is necessary to limit the harmfulness of these substances.
- 16 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 16012
Open AccessExposure to Endocrine Disruptors (Di(2-Ethylhexyl)phthalate (DEHP) and Bisphenol A (BPA)) in Women from Different Residing Areas in Italy: Data from the LIFE PERSUADED Project
Phthalates and bisphenol A (BPA) are plasticizers used in many industrial products that can act as endocrine disruptors and lead to metabolic diseases. During the LIFE PERSUADED project, we measured the urinary concentrations of BPA and Di(2-ethylhexyl)phthalate (DEHP) metabolites in 900 Italian women representative of the Italian female adult population (living in the north, centre, and south of Italy in both rural and urban areas). The whole cohort was exposed to DEHP and BPA with measurable levels above limit of detection in more than 99% and 95% of the samples, respectively. The exposure patterns differed for the two chemicals in the three macro-areas with the highest urinary levels for DEHP in south compared to central and northern Italy and for BPA in northern compared to central and southern Italy. BPA levels were higher in women living in urban areas, whereas no difference between areas was observed for DEHP. The estimated daily intake of BPA was 0.11 μg/kg per day, about 36-fold below the current temporary tolerable daily intake of 4 μg/kg per day established by the EFSA in 2015. The analysis of cumulative exposure showed a positive correlation between DEHP and BPA. Further, the reduction of exposure to DEHP and BPA, through specific legislative measures, is necessary to limit the harmfulness of these substances.
- Open Access
- 15 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15982
Functional and Taxonomic Traits of the Gut Microbiota in Type 1 Diabetes Children at the Onset: A Metaproteomic Study
Type 1 diabetes (T1D) is a chronic autoimmune metabolic disorder with onset in pediatric/adolescent age, characterized by insufficient insulin production, due to a progressive destruction of pancreatic β-cells. Evidence on the correlation between the human gut microbiota (GM) composition and T1D insurgence has been recently reported. In particular, 16S rRNA-based metagenomics has been intensively employed in the last decade in a number of investigations focused on GM representation in relation to a pre-disease state or to a response to clinical treatments. On the other hand, few works have been published using alternative functional omics, which is more suitable to provide a different interpretation of such a relationship. In this work, we pursued a comprehensive metaproteomic investigation on T1D children compared with a group of siblings (SIBL) and a reference control group (CTRL) composed of aged matched healthy subjects, with the aim of finding features in the T1D patients’ GM to be related with the onset of the disease. Modulated metaproteins were found either by comparing T1D with CTRL and SIBL or by stratifying T1D by insulin need (IN), as a proxy of β-cells damage, showing some functional and taxonomic traits of the GM, possibly related to the disease onset at different stages of severity.
- 15 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15982
Open AccessFunctional and Taxonomic Traits of the Gut Microbiota in Type 1 Diabetes Children at the Onset: A Metaproteomic Study
Type 1 diabetes (T1D) is a chronic autoimmune metabolic disorder with onset in pediatric/adolescent age, characterized by insufficient insulin production, due to a progressive destruction of pancreatic β-cells. Evidence on the correlation between the human gut microbiota (GM) composition and T1D insurgence has been recently reported. In particular, 16S rRNA-based metagenomics has been intensively employed in the last decade in a number of investigations focused on GM representation in relation to a pre-disease state or to a response to clinical treatments. On the other hand, few works have been published using alternative functional omics, which is more suitable to provide a different interpretation of such a relationship. In this work, we pursued a comprehensive metaproteomic investigation on T1D children compared with a group of siblings (SIBL) and a reference control group (CTRL) composed of aged matched healthy subjects, with the aim of finding features in the T1D patients’ GM to be related with the onset of the disease. Modulated metaproteins were found either by comparing T1D with CTRL and SIBL or by stratifying T1D by insulin need (IN), as a proxy of β-cells damage, showing some functional and taxonomic traits of the GM, possibly related to the disease onset at different stages of severity.
- Open Access
- 24 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (23) , 14650
Pathophysiology of Type 1 Diabetes and Gut Microbiota Role
Type 1 diabetes (T1D) is a multifactorial autoimmune disease driven by T-cells against the insulin-producing islet β-cells, resulting in a marked loss of β-cell mass and function. Although a genetic predisposal increases susceptibility, the role of epigenetic and environmental factors seems to be much more significant. A dysbiotic gut microbial profile has been associated with T1D patients. Moreover, new evidence propose that perturbation in gut microbiota may influence the T1D onset and progression. One of the prominent features in clinically silent phase before the onset of T1D is the presence of a microbiota characterized by low numbers of commensals butyrate producers, thus negatively influencing the gut permeability. The loss of gut permeability leads to the translocation of microbes and microbial metabolites and could lead to the activation of immune cells. Moreover, microbiota-based therapies to slow down disease progression or reverse T1D have shown promising results. Starting from this evidence, the correction of dysbiosis in early life of genetically susceptible individuals could help in promoting immune tolerance and thus in reducing the autoantibodies production. This review summarizes the associations between gut microbiota and T1D for future therapeutic perspectives and other exciting areas of research.
- 24 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (23) , 14650
Open AccessPathophysiology of Type 1 Diabetes and Gut Microbiota Role
Type 1 diabetes (T1D) is a multifactorial autoimmune disease driven by T-cells against the insulin-producing islet β-cells, resulting in a marked loss of β-cell mass and function. Although a genetic predisposal increases susceptibility, the role of epigenetic and environmental factors seems to be much more significant. A dysbiotic gut microbial profile has been associated with T1D patients. Moreover, new evidence propose that perturbation in gut microbiota may influence the T1D onset and progression. One of the prominent features in clinically silent phase before the onset of T1D is the presence of a microbiota characterized by low numbers of commensals butyrate producers, thus negatively influencing the gut permeability. The loss of gut permeability leads to the translocation of microbes and microbial metabolites and could lead to the activation of immune cells. Moreover, microbiota-based therapies to slow down disease progression or reverse T1D have shown promising results. Starting from this evidence, the correction of dysbiosis in early life of genetically susceptible individuals could help in promoting immune tolerance and thus in reducing the autoantibodies production. This review summarizes the associations between gut microbiota and T1D for future therapeutic perspectives and other exciting areas of research.
- Open Access
- 6 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (18) , 10256
Gut Microbiota Functional Traits, Blood pH, and Anti-GAD Antibodies Concur in the Clinical Characterization of T1D at Onset
Alterations of gut microbiota have been identified before clinical manifestation of type 1 diabetes (T1D). To identify the associations amongst gut microbiome profile, metabolism and disease markers, the 16S rRNA-based microbiota profiling and 1H-NMR metabolomic analysis were performed on stool samples of 52 T1D patients at onset, 17 T1D siblings and 57 healthy subjects (CTRL). Univariate, multivariate analyses and classification models were applied to clinical and -omic integrated datasets. In T1D patients and their siblings, Clostridiales and Dorea were increased and Dialister and Akkermansia were decreased compared to CTRL, while in T1D, Lachnospiraceae were higher and Collinsella was lower, compared to siblings and CTRL. Higher levels of isobutyrate, malonate, Clostridium, Enterobacteriaceae, Clostridiales, Bacteroidales, were associated to T1D compared to CTRL. Patients with higher anti-GAD levels showed low abundances of Roseburia, Faecalibacterium and Alistipes and those with normal blood pH and low serum HbA1c levels showed high levels of purine and pyrimidine intermediates. We detected specific gut microbiota profiles linked to both T1D at the onset and to diabetes familiarity. The presence of specific microbial and metabolic profiles in gut linked to anti-GAD levels and to blood acidosis can be considered as predictive biomarker associated progression and severity of T1D.
- 6 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (18) , 10256
Open AccessGut Microbiota Functional Traits, Blood pH, and Anti-GAD Antibodies Concur in the Clinical Characterization of T1D at Onset
Alterations of gut microbiota have been identified before clinical manifestation of type 1 diabetes (T1D). To identify the associations amongst gut microbiome profile, metabolism and disease markers, the 16S rRNA-based microbiota profiling and 1H-NMR metabolomic analysis were performed on stool samples of 52 T1D patients at onset, 17 T1D siblings and 57 healthy subjects (CTRL). Univariate, multivariate analyses and classification models were applied to clinical and -omic integrated datasets. In T1D patients and their siblings, Clostridiales and Dorea were increased and Dialister and Akkermansia were decreased compared to CTRL, while in T1D, Lachnospiraceae were higher and Collinsella was lower, compared to siblings and CTRL. Higher levels of isobutyrate, malonate, Clostridium, Enterobacteriaceae, Clostridiales, Bacteroidales, were associated to T1D compared to CTRL. Patients with higher anti-GAD levels showed low abundances of Roseburia, Faecalibacterium and Alistipes and those with normal blood pH and low serum HbA1c levels showed high levels of purine and pyrimidine intermediates. We detected specific gut microbiota profiles linked to both T1D at the onset and to diabetes familiarity. The presence of specific microbial and metabolic profiles in gut linked to anti-GAD levels and to blood acidosis can be considered as predictive biomarker associated progression and severity of T1D.